Close Menu

Peck Lecture 2019

Wednesday, April 17, 2019 - 15:15 to 16:30

Immunotherapy using chimeric antigen receptor (CAR) T cells has demonstrated high response rates in patients with B cell malignancies and offers further promise for additional hematological indications as well as potentially for solid tumors.  Engineered T cells represent a new paradigm in anti-cancer therapy.  CAR-T cells are generated by removing T cells from a patient's blood and engineering the cells to express the chimeric antigen receptor, which reprograms the T cells to target and destro

Event Tags: 

Subscribe to RSS - Peck Lecture 2019